161 related articles for article (PubMed ID: 8400608)
21. Salmon calcitonin in the prevention of bone loss at perimenopause.
Arnala I; Saastamoinen J; Alhava EM
Bone; 1996 Jun; 18(6):629-32. PubMed ID: 8806006
[TBL] [Abstract][Full Text] [Related]
22. Patient responsiveness to calcitonin salmon nasal spray: a subanalysis of a 2-year study.
Overgaard K; Lindsay R; Christiansen C
Clin Ther; 1995; 17(4):680-5. PubMed ID: 8565031
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover.
Tankó LB; Bagger YZ; Alexandersen P; Devogelaer JP; Reginster JY; Chick R; Olson M; Benmammar H; Mindeholm L; Azria M; Christiansen C
J Bone Miner Res; 2004 Sep; 19(9):1531-8. PubMed ID: 15312255
[TBL] [Abstract][Full Text] [Related]
24. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers.
Trovas GP; Lyritis GP; Galanos A; Raptou P; Constantelou E
J Bone Miner Res; 2002 Mar; 17(3):521-7. PubMed ID: 11874243
[TBL] [Abstract][Full Text] [Related]
25. [Clinical efficacy of treatment with salmon calcitonin, administered intranasally for 1 year, in stabilized postmenopausal osteoporosis].
Agnusdei D; Gonnelli S; Camporeale A; Batignani T; Nardi P; Ianes A; Gennari C
Minerva Endocrinol; 1989; 14(3):169-76. PubMed ID: 2695815
[TBL] [Abstract][Full Text] [Related]
26. Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients.
Wang SX; Li H
Chin Med J (Engl); 2008 Jul; 121(14):1280-4. PubMed ID: 18713548
[TBL] [Abstract][Full Text] [Related]
27. Calcitonin.
Silverman SL
Am J Med Sci; 1997 Jan; 313(1):13-6. PubMed ID: 9001161
[TBL] [Abstract][Full Text] [Related]
28. Effects of nasal administration of calcitonin in oophorectomized women: 2-year controlled double-blind study.
Grigoriou O; Papoulias I; Vitoratos N; Papadias C; Konidaris S; Antoniou G; Chryssikopoulos A
Maturitas; 1997 Dec; 28(2):147-51. PubMed ID: 9522322
[TBL] [Abstract][Full Text] [Related]
29. Preventive treatment of cortical bone loss with salmon nasal calcitonin in early postmenopausal women.
Mango D; Ricci S; Manna P; Natili G; Dell'Acqua S
Minerva Endocrinol; 1993 Sep; 18(3):115-21. PubMed ID: 8183178
[TBL] [Abstract][Full Text] [Related]
30. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.
Chesnut CH; Silverman S; Andriano K; Genant H; Gimona A; Harris S; Kiel D; LeBoff M; Maricic M; Miller P; Moniz C; Peacock M; Richardson P; Watts N; Baylink D
Am J Med; 2000 Sep; 109(4):267-76. PubMed ID: 10996576
[TBL] [Abstract][Full Text] [Related]
31. Prevention of postmenopausal bone loss by rectal calcitonin.
Reginster JY; Jupsin I; Deroisy R; Biquet I; Franchimont N; Franchimont P
Calcif Tissue Int; 1995 Jun; 56(6):539-42. PubMed ID: 7648483
[TBL] [Abstract][Full Text] [Related]
32. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis.
Adami S; Passeri M; Ortolani S; Broggini M; Carratelli L; Caruso I; Gandolini G; Gnessi L; Laurenzi M; Lombardi A
Bone; 1995 Oct; 17(4):383-90. PubMed ID: 8573412
[TBL] [Abstract][Full Text] [Related]
33. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
Binkley N; Bolognese M; Sidorowicz-Bialynicka A; Vally T; Trout R; Miller C; Buben CE; Gilligan JP; Krause DS;
J Bone Miner Res; 2012 Aug; 27(8):1821-9. PubMed ID: 22437792
[TBL] [Abstract][Full Text] [Related]
34. Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis.
Bandeira L; Lewiecki EM; Bilezikian JP
Expert Opin Drug Metab Toxicol; 2016 Jun; 12(6):681-9. PubMed ID: 27070719
[TBL] [Abstract][Full Text] [Related]
35. Early effect of nasal salmon calcitonin on the bone marker Crosslaps.
Ofluoglu D; Karadag-Saygi E; Canbulat C; Gunduz OH; Kul-Panza E; Akyuz G
Rheumatol Int; 2006 Feb; 26(4):288-91. PubMed ID: 15875189
[TBL] [Abstract][Full Text] [Related]
36. Analgesic effect of intranasal and intramuscular salmon calcitonin in post-menopausal osteoporosis: a double-blind, double-placebo study.
Pontiroli AE; Pajetta E; Scaglia L; Rubinacci A; Resmini G; Arrigoni M; Pozza G
Aging (Milano); 1994 Dec; 6(6):459-63. PubMed ID: 7748920
[TBL] [Abstract][Full Text] [Related]
37. Calcitonin for prevention and treatment of osteoporosis.
Reginster JY
Am J Med; 1993 Nov; 95(5A):44S-47S. PubMed ID: 8256795
[TBL] [Abstract][Full Text] [Related]
38. Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers.
Nielsen NM; von der Recke P; Hansen MA; Overgaard K; Christiansen C
Calcif Tissue Int; 1994 Jul; 55(1):8-11. PubMed ID: 7922794
[TBL] [Abstract][Full Text] [Related]
39. Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin.
Roux C; Pelissier C; Listrat V; Kolta S; Simonetta C; Guignard M; Dougados M; Amor B
Osteoporos Int; 1995 May; 5(3):185-90. PubMed ID: 7655179
[TBL] [Abstract][Full Text] [Related]
40. Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis.
Flicker L; Hopper JL; Larkins RG; Lichtenstein M; Buirski G; Wark JD
Osteoporos Int; 1997; 7(1):29-35. PubMed ID: 9102059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
